Release Details
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September
- A company presentation is scheduled at Baird’s 2016 Global Healthcare Conference on
Wednesday, September 7 th at9:40 a.m. ET - Management participation in a fireside chat is scheduled at the
Morgan Stanley Global Healthcare Conference onTuesday, September 13 th at10:00 a.m. ET
The audio portion of the presentation and fireside chat will be available on the investors page of the
About
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT:Patrick O'Brien Senior Vice President, Investor RelationsCoherus BioSciences, Inc. pobrien@coherus.com +1 (650) 649-3527